Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Biotech
Health
STAT+
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Adam's Take
STAT+

Gilead’s golden era ends with the executive departures of ‘The Johns’

  • Adam Feuerstein

By Adam Feuerstein July 25, 2018

Reprints
Paul Sakuma/AP

The Johns — Milligan and Martin — are leaving Gilead Sciences, marking a significant and uncertain transition in the executive offices of the large-cap biotech.

Milligan said Wednesday that he will step down as Gilead’s CEO and leave the company’s board at the end of the year. A replacement has not been named but Gilead’s board is starting a search.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Tags

Newly available test strips can detect lethal ‘tranq’ in…
Newly available test strips can detect lethal ‘tranq’ in drug supply
Wary of changes to Medicare Advantage, health insurers put…
Wary of changes to Medicare Advantage, health insurers put up a fight — and exaggerate the…
Novartis data set up multibillion-dollar battle over breast cancer…
Novartis data set up multibillion-dollar battle over breast cancer drugs
Bernie Sanders’ accidentally great drug pricing idea
Bernie Sanders’ accidentally great drug pricing idea
Under protest, FDA to convene advisory panel to review…
Under protest, FDA to convene advisory panel to review controversial cell therapy for ALS
With arrival of breakthrough therapies, a rare disease group…
With arrival of breakthrough therapies, a rare disease group reconsiders the possible — and its mission

Recommended Stories